Hepatitis C

There was not a statistically significant difference in eGFR between kidney recipients of HCV positive and negative donors.

Despite the increasing push for using HCV-positive organs to expand the donor pool, hundreds of livers allografts from donors are still not being used in transplantation.

Proactive efforts throughout the pandemic must be made to ensure this gap in primary and preventative care can be filled.

Adherence was also reported to be high, yet variable, with use of wireless pillboxes and video-based observed therapy.

Patients with hematological disorders like sickle cell disease or β-thalassemia are at high risk for HCV infection as a result of frequent transfusions.

The rates of ALT normalization maintained in both arms of the 96 week study.

The shortage of kidney donors begs a need to consider safe approaches to expand the donor pool.

HIV care may help enable better treatment for HCV infectious.

Investigators used CDC HCV infographic posters to remind healthcare providers and offer educational resources about screening.

A week-long treatment program prevented HCV transmission in 88% of cases.

In a study presented at ACG, investigators find the rate of confirmed HCV infections remained stable pre- and post-interventions.

New phase 1 data show the first-in-class oral therapy is not affected by the burden on metabolism via hepatic or renal disease.

This edition from the 10 Year Plan features perspective from leadership at WGO and Crohn's & Colitis Foundation, as well as survey results from gastroenterologists.

This article is the final installment of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

Dr. Yuen discusses some new treatments in the pipeline and how personalized medicine could make an impact in HBV treatment.

This article is the third in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

This article is the second in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

This article is the first in a series of 4 articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

The association of DAA treatment with mortality did not differ by sex in the cirrhosis group.

Low-level viremia was transiently detectable in 21 recipients in the early post-transplant period, but not after 14 days.

The approval of sofosbuvir and velpatasvir comes after a multicenter clinical trial confirmed the safety and efficacy of the treatment.

The US Preventive Services Task Force suggested that patients 18-79 years old should be screened regardless of known risk factors.

Younger hepatitis B patients had better odds at transplant-free survival after 6 months.

In a new study, investigators generate a global estimate for children with HCV infections in 249 countries and territories.